Inhibikase Therapeutics, Inc.
IKT
$2.40
$0.03861.64%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 36.22% | 11.79% | |||
| Gross Profit | -36.22% | -11.79% | |||
| SG&A Expenses | -17.07% | -2.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.38% | 5.61% | |||
| Operating Income | -15.38% | -5.61% | |||
| Income Before Tax | -16.50% | -6.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.50% | -6.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.50% | -6.67% | |||
| EBIT | -15.38% | -5.61% | |||
| EBITDA | -15.40% | -5.62% | |||
| EPS Basic | 1.17% | 10.24% | |||
| Normalized Basic EPS | 1.14% | 10.26% | |||
| EPS Diluted | 1.17% | 10.24% | |||
| Normalized Diluted EPS | 1.14% | 10.26% | |||
| Average Basic Shares Outstanding | 17.87% | 18.85% | |||
| Average Diluted Shares Outstanding | 17.87% | 18.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
